Exenatide: difference between revisions
Diff·revision 5 → 6·03:21, 8 Nov 2024
Difference between revision 5 and revision 6 of Exenatide. 6 lines changed; the page grew by 199 bytes.
| Revision 5 — 17:16, 1 Nov 2024 KarlFischerKit (talk) rm the comparison to a compound with no published head-to-head data 2,736 bytes +745 | Revision 6 — 03:21, 8 Nov 2024 SVG_Solomon (talk) space between number and unit per PP:MOS 2,935 bytes +199 | ||
|---|---|---|---|
| 5 | | Origin = Synthetic exendin-4 | 5 | | Origin = Synthetic exendin-4 |
| 6 | | First approval = 2005 | 6 | | First approval = 2005 |
| + | 7 | <!-- Properties --> | |
| + | 8 | | Residues = 39 | |
| + | 9 | | Molar mass = 4,186.6 g·mol⁻¹ | |
| + | 10 | | Half-life, immediate release = ≈2.4 h | |
| + | 11 | | Half-life, extended release = ≈2 weeks apparent | |
| 7 | }} | 12 | }} |
| 8 | 13 | ||
| ⋮ | ⋮ | ||
| 28 | [[Category:GLP-1 receptor agonists]] | 33 | [[Category:GLP-1 receptor agonists]] |
| 29 | [[Category:Peptide drugs]] | 34 | [[Category:Peptide drugs]] |
| + | 35 | [[Category:Pharmacokinetics]] | |
| 30 | 36 |